Abstract 193P
Background
Humanized immune system mice provide a useful platform for various immune research fields. However, there have been limitations such as insufficient engraftment of human cells and development of graft-versus-host disease (GVHD). To overcome the limitations, we generated a novel immunodeficient mouse strain, CD47; Prkdc; IL2rg triple KO (STKO) mice based on SID mice (Prkdc; IL2rg double KO). Because CD47 plays an important role in engraftment of human tissues and cells, we expected improved human cell engraftment and GvHD development in STKO mice.
Methods
4-week female SID and STKO mice were applied to generate HSC hu-mice. 1X105 hCD34+ HSCs were injected within 24 hours of myeloablation applying busulfan. For generating PBMC hu-mice 5X106 PBMCs were injected. To overcome lethal GvHD, low dose PBMCs were applied to 4 weeks old mice. The proportion of human leukocyte markers was analyzed by flow cytometry.
Results
As a result of HSC hu-mice analysis, the transplantation efficacy was enhanced that hCD45 of STKO exceeded 50% at 8 weeks after HSC transplantation, which was more than 50% greater than that of SID. The engraftment of hCD45 and hCD3 in STKO was significantly improved compared to SID until the last measurement and GvHD symptoms were also reduced in STKO. Similarly, the PBMC hu-mice studies showed that human leukocyte transplantation efficacy and GvHD symptoms were improved in STKO. Especially, in the study applying low-dose PBMC to young mice, long-term studies were possible with minimal clinical signs despite the significant human leukocyte engraftment.
Conclusions
In the HSC hu-mice and the PBMC hu-mice analyses, the transplantation and the differentiation of immune cells were significant, and GvHD symptoms were alleviated in STKO mice. To relieve GvHD symptoms, we applied low-dose PBMC to 4 week old mice and observed minimal health problems in STKO with improved human immune cell reconstitution. In conclusion, STKO mice is expected to be a novel and useful platform for various immune studies, considering enhanced transplantation efficiency with the stable health of the animal.
Legal entity responsible for the study
The animal study was approved and monitored by the Institutional Animal Care and Use Committee of Asan Institute for Life Sciences (Seoul, Korea, IACUC No. 2022-12-123).
Funding
National Research Foundation of Korea grant (NRF-2020R1C1C1014653).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract